NewLink Genetics Corp. priced an underwritten public offering of 5 million common shares at $10.25 apiece.
The company granted underwriters a 30-day option to buy up to an additional 750,000 common shares on the same terms and conditions.
The offering is expected to close by Oct. 6, subject to customary closing conditions.
NewLink Genetics plans to use net proceeds to fund research and development for its product candidates, in addition to working capital and general corporate purposes.
BofA Merrill Lynch and Stifel are acting as joint book-running managers for the offering, with Baird as co-manager.